Skip to main content
Fig. 3 | Stem Cell Research & Therapy

Fig. 3

From: Allogeneic bone marrow mesenchymal stem cell-derived exosomes alleviate human hypoxic AKI-on-a-Chip within a tight treatment window

Fig. 3

hBMMSC-Exos alleviate hypoxic injury of PT cells by decreasing epithelial permeability, increasing proliferation and polarity. (A) hBMMSC-Exos decreased the permeabilization of epithelial barrier against 20 kDa and 155 kDa Dextran. (n = 6) (B) The barrier integrity assay revealed amelioration of hypoxic injury on PT epithelial barrier upon 24th hour after hBMMSC-Exos treatment. (n = 6) (C) ZO-1 (Alexa Fluor 594) and acetylated α-tubulin (FITC) immunolabelling showed structurally intact and polarized PT epithelial cells in hBMMSC-Exos group compared to the loss of polarity in vehicle. (n = 10) (D) CTFI outputs revealed the increase of ZO-1 after hBMMSC-Exos treatment reversing the effects of hypoxic injury. (n = 10) (E) hBMMSC-Exos increased the proliferation rate of PT epithelial cells after acute hypoxic tubular injury (n = 12). Plotted data in scatter dot plots (C), (D) and (E) are mean ± SD. (*) denotes (p < 0.05) between indicated groups

Back to article page

Stem Cell Research & Therapy

ISSN: 1757-6512